作者
Jaclyn A Smith, Michael M Kitt, Alyn H Morice, Surinder S Birring, Lorcan P McGarvey, Mandel R Sher, Yu-Ping Li, Wen-Chi Wu, Zhi Jin Xu, David R Muccino, Anthony P Ford, Jaclyn Smith, Lorcan McGarvey, Surinder Birring, James Hull, Warner W Carr, Alan B Goldsobel, Gary N Gross, John R Holcomb, Iftikhar Hussain, Mandel Sher, Selwyn Spangenthal, William Storms, Alyn Morice, David Elkayam, Gary C Steven, James Krainson, Faisal Alfonso Fakih, Jonathan Matz, Gregory Daniel Brooks, Thomas Casale, Gary D Berman, John J Condemi, Leon S Greos, Shaila U Gogate, Ellen R Sher, Jason H Friesen, Eric J Schenkel, David Isaac Bernstein, Jonathan Corren, Krishna Sundar, Mark H Gotfried, Anthony Montanaro, William R Lumry, Niran J Amar, Michael S Kaplan, Bruce M Prenner, Thomas R Murphy, James S Good, Sean Parker, Tim Harrison, Ian Pavord, Christopher Brightling, Ratko Djukanovic, Douglas McQuaid, Michael Denenberg, Neil A Ettinger, Vivek Iyer
发表日期
2020/8/1
期刊
The Lancet Respiratory Medicine
卷号
8
期号
8
页码范围
775-785
出版商
Elsevier
简介
Background
Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatment for refractory chronic cough or unexplained chronic cough.
Methods
We did a 12-week, phase 2b, randomised, double-blind, placebo-controlled study in patients with refractory chronic cough or unexplained chronic cough aged 18–80 years who were recruited from 44 primarily outpatient pulmonologist or allergist sites in the UK and the USA. Eligible patients had refractory or unexplained chronic cough lasting 1 year or longer, no radiographic chest abnormality, and 40 mm or more on a 100-mm cough severity visual analogue scale at enrolment. Patients were randomly assigned to receive placebo or one of three doses (7·5 mg, 20 mg, or 50 mg) of oral gefapixant …
学术搜索中的文章
JA Smith, MM Kitt, AH Morice, SS Birring, LP McGarvey… - The Lancet Respiratory Medicine, 2020